在多焦运动神经病变的iPSC衍生的运动神经元模型中,IgM抗lioside结合和补充激活
Daniëlle Krijgsman1, Kim Dijkxhoorn1, Elisabeth de Zeeuw1
1Center for Translational Immunology, UMC Utrecht, the Netherlands.
Neurology(R) neuroimmunology & neuroinflammation
|November 12, 2025
概括
多焦点运动神经病变 (MMN) 中的IgM自身抗体在运动神经元上激活补充,与疾病严重程度相关. 补充抑制剂显示为MMN的向治疗有前途.
科学领域:
- 神经免疫学 神经免疫学
- 干细胞生物学 干细胞生物学
- 神经肌肉疾病 神经肌肉疾病
背景情况:
- 多焦点运动神经病变 (MMN) 的特征在于IgM自身抗体向化物,特别是GM1.
- 补充激活在MMN发病过程中的作用及其与临床表现的相关性仍然不完全理解.
研究的目的:
- 调查IgM血清阳性,补充激活和MMN中的临床参数之间的关系.
- 评估IV免疫球蛋白 (IVIg) 和补充抑制剂在诱导多能干细胞 (iPSC) 衍生的运动神经元 (MN) 模型中的有效性.
主要方法:
- 来自137名MMN患者的血清样本被用于评估IgM结合和C3对iPSCMN的固定.
- 在抗体结合,补充固定和临床参数 (MRC总分) 之间进行了相关性分析.
- 在iPSC MN模型中测试了IVIg和补充抑制剂在预防C3固定方面的有效性.
主要成果:
- 与对照组相比,在MMN患者样本中观察到IgM结合和补充激活 (C3固定) 的增加.
- 较高的抗体结合与增加的C3固定,肌肉软弱和较高的IVIg剂量相关.
- 补充剂激活,而不是单独结合IgM,与感官异常,手臂MRI发现和轴突损伤相关.
结论:
- 在MMN中的IgM抗体诱导iPSC MNs上的补充激活,与临床结果有显著的相关性.
- 在iPSC MN模型中,补充抑制剂在防止补充激活方面表现出高效.
- iPSC MN模型作为一种可行的平台,用于新型MMN疗法的临床前查.
相关概念视频
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...